<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02688140</url>
  </required_header>
  <id_info>
    <org_study_id>TUD-APOLLO-064</org_study_id>
    <nct_id>NCT02688140</nct_id>
  </id_info>
  <brief_title>Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia</brief_title>
  <acronym>TUD-APOLLO-064</acronym>
  <official_title>A Randomized Phase III Study to Compare Arsenic Trioxide (ATO) Combined to ATRA and Idarubicin Versus Standard ATRA and Anthracyclines-based Chemotherapy (AIDA Regimen) for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität Dresden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gruppo Italiano Malattie EMatologiche dell'Adulto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Groupe Francophone des Myelodysplasies</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Haemato Oncology Foundation for Adults in the Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Programa para el Tratamiento de Hemopatías Malignas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>German Federal Ministry of Education and Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Teva Pharmaceuticals Europe</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Technische Universität Dresden</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute promyelocytic leukemia (APL) is a rare subtype of acute myeloid leukemia (AML)
      characterized by consistent clinical, morphologic, and genetic features. According to the FAB
      classification APL is designated as&quot;M3 leukemia&quot; and assigned to the WHO defined type of AML
      with recurrent cytogenetic abnormalities, &quot;acute promyelocytic leukemia with
      t(15;17)(q22;q12), (PML/RARα) and variants&quot;.

      Despite the dramatic progress achieved in frontline therapy of APL with ATRA plus
      anthracycline-based regimens, relapses still occur in approximately 20% of patients.
      Moreover, these regimens are associated with significant toxicities due to severe
      myelosuppression frequently associated with life-threatening infections and potentially
      serious late effects including development of secondary MDS/AML. In a recent randomized
      clinical trial in low/intermediate-risk APL (WBC ≤ 10 GPt/l APL0406 trial) a combination of
      arsenic trioxide (ATO) and ATRA has been shown to result into better survival with
      significantly lower toxicity rates compared to the standard ATRA + idarubicin (AIDA) therapy.
      Inspired by the results of this trial the investigators intend to perform a randomized study
      in high-risk APL (WBC at diagnosis &gt; 10 GPt/l) comparing standard AIDA-based treatment with
      ATO/ATRA combination including low-doses idarubicin during induction. The investigators
      propose a modified ATO/ATRA protocol with the addition of two doses of IDA (50% compared to
      standard AIDA induction) for induction because of the anticipated need of adding
      anthracyclines to control hyperleukocytosis and to achieve long-term disease control in this
      high-risk APL population. This is followed by 4 cycles of ATO/ATRA consolidation therapy. As
      in the APL0406 study for low/intermediate-risk patients the investigators expect less severe
      hematologic toxicity and treatment-related mortality resulting in an improved outcome for
      patients in the experimental arm. Furthermore, from the start of consolidation, these
      patients (in contrast to the standard arm) can be treated on an outpatient basis, which is
      also considered to be associated with an improved quality of life. The study will be
      conducted as a European intergroup study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>From date of randomization until the date of first documented event, assessed up to 66 months</time_frame>
    <description>events are: no achievement of haematological complete remission after induction therapy; no achievement of molecular remission after the last consolidation course; relapse; death including early death or development of secondary AML or MDS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of hematological complete remission</measure>
    <time_frame>up to 60 days, from date of randomization until end of induction therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of early death within 30 days after randomization</measure>
    <time_frame>up to 30 days after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of overall survival (OS)</measure>
    <time_frame>at 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of cumulative incidence of secondary MDS or AML</measure>
    <time_frame>assessed up to 66 months, from date of randomization until occurance of secondary AML or MDS</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of cumulative incidence of relapse (CIR)</measure>
    <time_frame>at 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hematological and non-hematological toxicity</measure>
    <time_frame>assessed up to 30 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of molecular remission after the last consolidation cycle</measure>
    <time_frame>up to 256 days after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of acute promyelocytic leukemia/RARa transcript level reduction after induction therapy until end of study</measure>
    <time_frame>assessed up to 30 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life at the end of induction therapy until the end of study</measure>
    <time_frame>assessed up to 30 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To investigate differences in the immune reconstitution between the two arms</measure>
    <time_frame>assessed up to 30 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total hospitalization days during therapy</measure>
    <time_frame>assessed up to 30 months after randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Acute Promyelocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction therapy: Patients receive idarubicin i.v. over 20 minutes on day 1 and 3, oral tretinoin twice daily on day 1-28 (max. up to day 60) and arsenic trioxide i.v. over 2 hours on day 5-28 (max. up to day 60).
In case of morphological CR and regenerated blood counts, consolidation therapy should be started within 2-4 weeks after documented CR.
Consolidation therapy: Patients receive oral tretinoin twice daily on day 1-14. Treatment with tretinoin repeats every 4 weeks for up to 7 courses. Patients also receive arsenic trioxide i.v. over 2 hours on days 1-5 in week 1-4. Treatment with arsenic trioxide repeats every 8 weeks for up to 4 courses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (standard chemotherapy)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Induction therapy: Patients receive idarubicin i.v. over 20 minutes on day 1,3,5 and 7 and oral tretinoin twice daily on day 1-28 (max. up to day 60). In case of morphological CR and regenerated blood counts, consolidation therapy should be started within 2-4 weeks after documented CR
Consolidation therapy: Patients receive oral tretinoin twice daily on day 1-45, idarubicin i.v. over 20 minutes on day 1-4 and day 31, cytarabine i.v. over 3 hours on day 1-4, over 8 hours on day 31-35, mitoxantrone i.v. over 30 minutes on day 16-20.
Maintenance therapy (only for PML-RARa negative patients): Patients receive oral mercaptopurine once daily and methotrexate i.m./p.o. once weekly for 3 months. Treatment with mercaptopurine and methotrexate repeats every 3 months for 7 courses. After completion of course 1 of mercaptopurine and methotrexate, patients receive oral tretinoin once daily on days 1-15. Treatment with tretinoin repeats every 3 months for 6 courses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arsenic trioxide</intervention_name>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>ATO</other_name>
    <other_name>Trisenox (R)</other_name>
    <other_name>As2O3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idarubicin</intervention_name>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B (standard chemotherapy)</arm_group_label>
    <other_name>IDA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <arm_group_label>Arm B (standard chemotherapy)</arm_group_label>
    <other_name>Ara-C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tretinoin</intervention_name>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B (standard chemotherapy)</arm_group_label>
    <other_name>all-trans retinoic acid</other_name>
    <other_name>ATRA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitoxantrone</intervention_name>
    <arm_group_label>Arm B (standard chemotherapy)</arm_group_label>
    <other_name>MTZ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mercaptopurine</intervention_name>
    <arm_group_label>Arm B (standard chemotherapy)</arm_group_label>
    <other_name>6-Mercaptopurine</other_name>
    <other_name>6-MP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <arm_group_label>Arm B (standard chemotherapy)</arm_group_label>
    <other_name>MTX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent

          -  Women or men with a newly diagnosed APL by cytomorphology, confirmed by molecular
             analysis*

          -  Age ≥ 18 and ≤ 65 years

          -  ECOG performance status 0-3

          -  WBC at diagnosis &gt; 10 GPt/l

          -  Serum total bilirubin ≤ 3.0 mg/dl (≤ 51 µmol/l)

          -  Serum creatinine ≤ 3.0 mg/dl (≤ 260 µmol/l)

          -  Women must fulfill at least one of the following criteria in order to be eligible for
             trial inclusion:

          -  Post-menopausal (12 months of natural amenorrhea or 6 months of amenorrhea with Serum
             FSH &gt; 40 U/ml)

          -  Postoperative (i.e. 6 weeks) after bilateral ovariectomy with or without hysterectomy

          -  Continuous and correct application of a contraception method with a Pearl Index of &lt;1%
             (e.g. implants, depots, oral contraceptives, -intrauterine device - IUD)

          -  Sexual abstinence

          -  Vasectomy of the sexual partner

               -  The confirmation of diagnosis at genetic level (microspeckled PML nuclear
                  distribution by PGM3 monoclonal antibody and/or PML/RARa fusion by RT-PCR or
                  fluorescence in situ hybridization (FISH) and/or demonstration of t(15;17) at
                  karyotyping) will be mandatory for patient eligibility. However, in order to
                  avoid delay in treatment initiation, patients can be randomized on the basis of
                  morphologic diagnosis only and before the results of genetic tests are available

        Exclusion Criteria:

          -  Patients who are not eligible for chemotherapy as per discretion of the treating
             physician

          -  APL secondary to previous radio- or chemotherapy for non-APL disease

          -  Other active malignancy at time of study entry (exception: basal-cell carcinoma)

          -  Lack of diagnostic confirmation at genetic level

          -  Significant arrhythmias, ECG abnormalities:

          -  Congenital long QT syndrome;

          -  History or presence of significant ventricular or atrial tachyarrhythmia;

          -  Clinically significant resting bradycardia (&lt;50 beats per minute)

          -  QTc &gt;500msec on screening ECG for both genders (using the QTcF formula detailed on
             protocol)

          -  Right bundle branch block plus left anterior hemiblock, bifascicular block

          -  Other cardiac contraindications for intensive chemotherapy (L-VEF &lt;50%)

          -  Uncontrolled, life-threatening infections

          -  Severe non controlled pulmonary or cardiac disease

          -  Severe hepatic or renal dysfunction

          -  HIV and/or active hepatitis C infection

          -  Pregnant or breast-feeding patients

          -  Allergy to trial medication or excipients in study medication

          -  Substance abuse; medical, psychological or social conditions that may interfere with
             the patients participation in the study or evaluation of the study results

          -  Use of other investigational drugs at the time of enrolment or within 30 days before
             study entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Uwe Platzbecker, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Technische Universität Dresden (TUD)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Uwe Platzbecker, Prof. Dr.</last_name>
    <phone>+49 351 458</phone>
    <phone_ext>3192</phone_ext>
    <email>uwe.platzbecker@uniklinikum-dresden.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michaela Sauer</last_name>
    <phone>+49 351 458</phone>
    <phone_ext>3192</phone_ext>
    <email>michaela.sauer@uniklinikum-dresden.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>French-Belgian-Swiss APL study group</name>
      <address>
        <city>All Participating Sites</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre Fenaux, Prof. Dr.</last_name>
      <email>pierre.fenaux@avc.ap-hop-paris.fr</email>
    </contact>
    <contact_backup>
      <last_name>Lionel Ades, Dr.</last_name>
      <email>lionel.ades@sls.aphp.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>AML-CG study group</name>
      <address>
        <city>All Participating Sites</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eva Lengfelder, Prof. Dr.</last_name>
      <email>Eva.Lengfelder@umm.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AML-SG study group</name>
      <address>
        <city>All Participating Sites</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard F. Schlenk, Prof. Dr.</last_name>
      <email>Richard.Schlenk@uniklinik-ulm.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>OSHO study group</name>
      <address>
        <city>All Participating Sites</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dietger Niederwieser, Prof. Dr.</last_name>
      <email>Dietger.Niederwieser@medizin.uni-leipzig.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>SAL study group</name>
      <address>
        <city>All Participating Sites</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Uwe Platzbecker, Prof. Dr.</last_name>
      <phone>+49 351 458</phone>
      <phone_ext>3192</phone_ext>
      <email>uwe.platzbecker@uniklinikum-dresden.de</email>
    </contact>
    <contact_backup>
      <last_name>Michaela Sauer</last_name>
      <phone>+49 351 458</phone>
      <phone_ext>3192</phone_ext>
      <email>michaela.sauer@uniklinikum-dresden.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GIMEMA study group</name>
      <address>
        <city>All Participating Sites</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francesco Lo-Coco, Prof. Dr.</last_name>
      <email>Francesco.lo.coco@uniroma2.it</email>
    </contact>
    <contact_backup>
      <last_name>Fabio Efficace, Dr.</last_name>
      <email>f.efficace@gimema.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>HOVON study group</name>
      <address>
        <city>All Participating Sites</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Edo Vellenga, Prof. Dr.</last_name>
      <email>e.vellenga@umcg.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>PETHEMA study group</name>
      <address>
        <city>All Participating Sites</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Miguel A. Sanz, Prof. Dr.</last_name>
      <email>sanz_mig@gva.es</email>
    </contact>
    <contact_backup>
      <last_name>Pau Montesinos, Prof. Dr.</last_name>
      <email>montesinos_pau@gva.es</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 11, 2016</study_first_submitted>
  <study_first_submitted_qc>February 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2016</study_first_posted>
  <last_update_submitted>August 4, 2017</last_update_submitted>
  <last_update_submitted_qc>August 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>APL</keyword>
  <keyword>acute promyelocytic leukemia (M3)</keyword>
  <keyword>high-risk acute promyelocytic leukemia (APL/AML M3)</keyword>
  <keyword>acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>newly diagnosed</keyword>
  <keyword>high-risk</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Promyelocytic, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>6-Mercaptopurine</mesh_term>
    <mesh_term>Tretinoin</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
    <mesh_term>Arsenic trioxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

